Диссертация (1154329), страница 31
Текст из файла (страница 31)
Green tea epigallocatechingallate shows a pronounced growth inhibitory effect on cancerous cellsbut not on their normal counterparts. Cancer Lett 1998; 129: 173–179.88.Chinnakannu K., Chen D., Li Y., Wang Z., Dou Q.P., Reddy G.P., SarkarF.H. Cell cycle-dependent effects of 3,3’-diindolylmethane onproliferation and apoptosis of prostate cancer cells.
J Cell Physiol. 2009,219:94–99.19089.Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycysticovary syndrome and the risk of gynaecological cancer: a systematicreview. Reprod Biomed Online 2009; 19:398–405.90.Chow H.H., Cai Y., Alberts D.S., Hakim I., Dorr R., Shahi F., CrowellJ.A., Yang C.S., Hara Y.
Phase I pharmacokinetic study of teapolyphenols following single-dose administration of epigallocatechingallate and polyphenon E. Cancer Epidemiol Biomarkers Prev. 2001;10(1):53-8.91.Chu E.C., Tarnawski A.S. PTEN regulatory functions in tumorsuppression and cell biology. Med Sci Monit 2004; 10: 235-241.92.Coffey D.S. In: Lepor H, Lawson RK (eds) The Molecular Biology ofthe Prostate. Saunders, Philadelphia, 1993, pp 28–56.93.Costa FF, Paixão VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA,Jr, et al. SATR-1 hypomethylation is a common and early event in breastcancer. Cancer Genet Cytogenet.
2006;165:135–143.94.Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002; 420,860–867.95.Culig Z. Androgen receptor cross-talk with cell signalling pathways.Growth factors. 2004; 22(3):179-84.96.Daga A., Ansari A., Patel S., Mirza S., Rawal R., Umrania V. Currentdrugs and drug targets in non-small cell lung cancer: limitations andopportunities. Asian Pac J Cancer Prev. 2015; 16(10):4147-56.97.Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylaseinhibitor-induced RelA/p65 acetylation and NFkappaB activationpotentiates apoptosis in leukemia cells through a process mediated byoxidative damage, XIAP downregulation, and -Jun Nterminal kinase 1activation.
Mol. Cell Biol. 2005; 25, 5429-4498.Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L., BjeldanesL.F. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary191hormone metabolites in postmenopausal women with a history of earlystage breast cancer. Nutr Cancer.
2004; 50(2):161-7.99.Darnell J.E. Transcription factors as targets for cancer therapy. Nat RevCancer 2002; 2: 740–749.100.Day BD, Dunson DB, Hill MC, Cousins D, Schectman JM. Highcumulative incidence of uterine leiomyoma in Black and White women:ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100–7.101.Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance.Nat Rev Cancer 2005; 5(4):275-284.102.Di Cristofano A, Pandolfi PP.
The multiple roles of PTEN in tumorsuppression. Cell 2000; 100: 387–390.103.Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P,Jackson R, Southgate C, Singh R, Falconer A et al. Two percent of menwith early-onset prostate cancer harbor germline mutations in theBRCA2 gene. Am J Hum Genet 2003; 1:1–12.104.Ellem S.J., Risbridger G.P. Aromatase and regulating theestrogen:androgen ratio in the prostate gland. J Steroid Biochem MolBiol. 2010; 118(4-5):246-251;105.Ellem S.J., Risbridger G.P. Treating prostate cancer: a rationale fortargeting local oestrogens.
Nature Reviews. Cancer 2007; 7(8):621-7.106.Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X,Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation insporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92:564–569.107.Fajardo A.M., Piazza G.A. Chemoprevention in gastrointestinalphysiology and disease. Anti-inflammatory approaches for colorectalcancer chemoprevention. Am J Physiol Gastrointest Liver Physiol. 2015;309(2):G59-70.192108.Fan S., Meng Q., Auborn K., et al.
(2006) BRCA1 and BRCA2 asmolecular targets for phytochemical indole-3-carbinol and genistein inbreast and prostate cancer cells. British J. Cancer, 94, 407–442.109.Fan S., Meng Q., Saha T., Sarkar F.H., Rosen E.M. Lowconcentrations of diindolylmethane, a metabolite of indole-3-carbinol,protect against oxidative stress in a BRCA1-dependent manner. CancerRes. 2009; 69(15):6083-91.110.Fang M., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., YangC. Teapolyphenol(-)-epigallocatechin-3-gallate inhibits DNAmethyltransferase and reactivates methylation-silenced genes in cancercell lines. Cancer Research 2003; 63, 7563.111.FarabegoliF.,BarbiC.,LambertiniE.,PivaR.(-)-Epigallocatechin-3-gallate downregulates estrogen receptor alphafunction in MCF-7 breast carcinoma cells. Cancer Detect Prev 2007;31(6):499-504.112.Feinberg A.P., Ohlsson R., Henikoff S.
The epigenetic progenitororigin of human cancer Nat. Rev. Genet., 7 (2006), pp. 21–33.113.Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, Wei H, Tian Z:Identification and characterization of cancer stem-like cells fromprimary carcinoma of the cervix uteri. Oncol Rep 2009, 22(5):11291134.114.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM:Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer 2010, 127(12):2893-2917115.Fisher R.P., Morgan D.O. A novel cyclin associates withMO15/CDK7 to form the CDK-activating kinase.
Cell 1994; 78, 713.116.Fishman J., Osborne M.P., Telang N.T. The role of estrogen inmammary carcinogenesis. Ann. NY Acad. Sci., 1995; 768, 91–100.193117.Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity andpenetrance analysis of the BRCA1 and BRCA2 genes in breast cancerfamilies: The Breast Cancer Linkage Consortium. Am J Hum Genet62:676-689, 1998.118.Fujiki H., Sueoka E., Watanabe T., Suganuma M. Primary cancerprevention by green tea, and tertiary cancer prevention by thecombination of green tea catechins and anticancer compounds.
J CancerPrev. 2015; 20(1):1-4.119.Fujiki H., Suganuma M., Okabe S., Kurusu M., Imai K., NakachiK. Involvement of TNF-alpha changes in human cancer development,prevention and palliative care. Mech Ageing Dev. 2002; 123(12):165563.120.Fujiki H., Suganuma M., Okabe S., Sueoka E., Suga K., Imai K.,Nakachi K.
A new concept of tumor promotion by tumor necrosis factoralpha, and cancer preventive agents (-)-epigallocatechin gallate andgreen tea--a review. Cancer Detect Prev. 2000; 24(1):91-9.121.Gama R.R., Giovanini A, de Rosa FS, Ogata DC, de Oliveira AL,Cardoso Costa AF6, Talini C, Feniman D, Kamei D, Júnior CF, Coco A,Carvalho AL.
Chemopreventive effects of the polyunsaturated fattyacids omega-3 on the carcinogenesis process of the upper aerodigestivetractinducedby4-nitroquinoline-1-oxideinSwissmice.Ecancermedicalscience. 2014; 8:392.122.Genazzani AR, Gadducci A, Gambacciani M. Controversial issuesin climactericmedicine II. Hormone replacement therapy and cancer.International Menopause Society Expert Workshop.
9–12 June 2001,Opera delDuomo, Pisa, Italy. Climacteric 2001; 4:181–193;123.Gold L.I., Saxena B., Mittal K.R., Marmor M., Goswami S.,Nactigal L., Korc M., Demopoulos R.I. Increased expression oftransforming growth factor beta isoforms and basic fibroblast growth194factor in complex hyperplasia and adenocarcinoma of the endometrium:evidence for paracrine and autocrine action. Cancer Res.
1994;54(9):2347-58.124.Goodwin P.J., Deboer G., Clark R.M. Cyclical mastopathy andpremenopausal breast cancer risk: results of a case-control study. BreastCancer Res Treat 1994; 33:63–73.125.Gopalakrishnan A., Tony Kong A.N. Anticarcinogenesis by dietaryphytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicityby modulation of transcription factors NF-κB and AP-1 in abnormalcancer cells.
Food Chem Toxicol 2008; 46: 1257–70.126.Gravitt P.E. The known unknowns of HPV natural history. J ClinInvest. 2011; 121:4593–4599.127.Grechukhina O., Petracco R, Popkhadze S, Massasa E, ParanjapeT, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let7 microRNA binding site of KRAS in women with endometriosis.EMBO Mol Med. 2012 Mar;4(3):206-17.128.Greger V, Passarge E, Höpping W, Messmer E, Horsthemke B.Epigenetic changes may contribute to the formation and spontaneousregression of retinoblastoma.
Hum Genet. 1989; 83:155–158.129.Grm H.S., Bergant M., Banks L. Human papillomavirus infection,cancer & therapy. Indian J Med Res. 2009; 130:277–85.130.Guimarães M.V., Michelin M.A., Lucena A.A., Lodi C.T., LimaM.I., Murta E.F., Melo V.H. Cytokine expression in the cervical stromaof HIV-positive and HIV-negative women with cervical intraepithelialneoplasia.Viral Immunol. 2014; 27(7):350-5.131.Haas K., Johannes C, Geisen C, Schmidt T, Karsunky H, Blass-Kampmann S, Obe G, Möröy T.
Malignant transformation by cyclin Eand Ha-Ras correlates with lower sensitivity towards induction of cell195death but requires functional Myc and CDK4. Oncogene. 1997;15(21):2615-23.132.Haefner B. NF-kB: arresting a major culprit in cancer. Drug DiscovToday 2002; 7:653–63.133.Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., RobsonC.N. Upregulation and nuclear recruitment of HDAC1 in hormonerefractory prostate cancer. Prostate. 2004; 59(2):177-89.134.Hall M., Peters G.
Genetic alterations of cyclins, cyclin-dependentkinases, and CDK inhibitors in human cancer. Adv. Cancer Res. 1996;68, 67.135.Haoula Z, Salman M, Atiomo W. Evaluating the associationbetween endometrial cancer and polycystic ovary syndrome. HumReprod 2012; 27:1327–1331.136.Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome andendometrial carcinoma. Lancet 2003; 361:1810–1812.137.Hardman W.E.
(n-3) fatty acids and cancer therapy. J Nutr., 134(12Suppl): 3427S-3430S.138.Hardman W.E. Omega-3 fatty acids to augment cancer therapy. JNutr, 2002; 132:3508S–12S.139.Hartmann L.C., Sellers T.A., Frost M.H., Lingle W.L., DegnimA.C., Ghosh K., Vierkant R.A., Maloney S.D., Pankratz V.S., HillmanD.W., Suman V.J., Johnson J., Blake C., Tlsty T., Vachon C.M., MeltonIII L.J., Visscher D.W. Benign breast disease and the risk of breastcancer. N Engl J Med 2005; 353:229–237.140.Hayakawa S., Saeki K., Sazuka M., Suzuki Y., Shoji Y., Ohta T.,Kaji K., You A., Isemura M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
